INNOVATIVE SCIENCES, INC. ANNOUNCES INITIAL PUBLIC OFFERING
PETALUMA, CA-- (January 24, 2007)—Oculus
Innovative Sciences, Inc. announced that it commenced today
its initial public offering of 3,025,000 shares of its Common
Stock at $8.00 per share. Roth Capital Partners acted as
book-running manager for this offering, and Maxim Group LLC
and Brookstreet Securities Corporation acted as co-managers.
All of the shares were sold by the Company.
The Company has granted the underwriters an option to purchase
an additional 453,750 shares to cover over-allotments, if
any. Oculus Innovative Science’s Common Stock will
be traded on the Nasdaq Global Market beginning January 25,
2007 under the symbol “OCLS.” The offering is
expected to close on January 30, 2007, subject to customary
A Prospectus relating to these securities
may be obtained from Roth Capital Partners, by mail at 24
Corporate Plaza Drive, Newport Beach, CA 92660, Attn: Lou
Ellis, Capital Markets, by telephone at (800) 990-2788 or
by e-mail request to RothECM@rothcp.com.
A registration statement relating to these
securities was declared effective by the Securities and Exchange
Commission on January 24, 2007. This press release shall
not constitute an offer to sell or the solicitation of an
offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
Oculus Innovative Sciences, Inc. is a medical technology
company focused on the development, manufacture and marketing
of a family of products intended to help prevent and treat
infection in acute and chronic wounds. Oculus’ platform
technology, called Microcyn®,
is a non-irritating, super-oxidized, water-based solution
that is designed to treat a wide range of pathogens, including
antibiotic-resistant strains of bacteria, as well as viruses,
fungi and spores.
Oculus’ principal operations are
in Petaluma, California, and it conducts operations in Europe
and Latin America through its wholly owned subsidiaries,
Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies
of Mexico, S.A. de C.V. Our website is www.oculusis.com.
Oculus Innovative Sciences,
Director of Communications and Investor Relations (425)
The Ruth Group
John Quirk / Sara Ephraim (investors)
(646) 536-7029 / 7002
Jason Rando / Janine McCargo (media)
(646) 536-7025 / 7033
PDF: 108 KB)